The National Copyright Administration has issued the "15th Five-Year Plan for Copyright Work," outlining key targets through 2030. The plan sets a national work registration target of 9.5 million pieces by 2030, up from 7.49 million in 2025, while computer software copyright registrations are projected to grow to 4 million from 3.18 million. Copyright pledge financing registrations are expected to reach 12 billion yuan by 2030, compared to 8.4 billion yuan in 2025, with the copyright industry's contribution to GDP targeted to rise from 7.46% to 7.53% over the same period.
The core copyright industry's GDP share is slated to increase from 4.72% to 4.79%. These regulatory developments have implications for Hong Kong-listed stocks including Vobile Group Ltd (03738) and China Literature Ltd (00772), as the copyright landscape evolves.
US markets were closed on Monday, September 7, in observance of the Labor Day holiday, providing a pause in global trading activity.
The yen has surged to its highest level since February, surpassing the peak reached following coordinated intervention by Japanese and US authorities. The currency climbed as much as 1.4% to 154.06 against the dollar, driven by intensifying market expectations that the Bank of Japan will raise interest rates, triggering a dramatic shift in market sentiment.
The Ministry of Industry and Information Technology has released its "15th Five-Year Plan for the Information and Communication Industry," announcing plans to launch 6G commercial services at an appropriate time, with a goal of fully building a new-generation communication network with leading performance by 2030. The plan calls for advancing urban and hotspot area networks toward "dual 10-gigabit" evolution, deepening 5G coverage in key scenarios, and extending 5G-Advanced network continuous coverage across county-level urban areas, expanding toward key townships to achieve 10-gigabit downlink and gigabit uplink peak rates in urban hotspots.
The ministry also emphasizes expanding 10-gigabit optical network pilot construction, implementing the "signal upgrade" special action to enhance end-to-end service perception, and promoting wide-area coverage of mobile IoT. Efforts will focus on advancing IPv6 technology innovation and integrated applications. These initiatives are relevant to Hong Kong-listed telecommunications equipment companies including ZTE Corp (00763).
The plan also promotes the construction of computing power transmission channels, deploying 400G and above high-speed transmission technologies, building direct fiber links, and pushing 100G optical network equipment further down the network. This benefits Hong Kong-listed optical communications stocks such as Cambridge Industries Group (06166), Zhongji Innolight (03308), and Yangtze Optical Fibre and Cable (06869).
Additionally, the government will improve computing power internet identifier systems, accelerate the coordinated development of computing and electricity, and promote the full-process integration of "computing, storage, network, electricity, and carbon" resources. Regular automated monitoring of energy efficiency, computing efficiency, and green electricity utilization rates will be established to achieve full-chain traceability of green electricity and green computing power. The plan includes developing a "green computing power" evaluation system, researching and issuing green computing power certificates, cultivating computing power application markets, and organizing international exchange activities for computing power enterprises. Yue Gang Wan Smart Computing (01396) is among the Hong Kong-listed companies involved in the six-network integration initiative.
CICC has announced that China Securities Regulatory Commission has approved its proposed absorption and merger of Dongxing Securities and Xinda Securities through an A-share issuance and share exchange, effective September 7, 2026. CICC plans to issue 3.104 billion new shares, with Oriental Asset Management and Xinda Asset Management approved as principal shareholders, holding 637 million shares (8.03%) and 1.329 billion shares (16.76%) respectively after the issuance. The company's A-shares will be suspended from trading starting September 15, 2026, and will resume trading on the day results of the A-share dissenting shareholders' purchase request are announced.
Viva Goods Company Ltd (00933) has announced that its wholly-owned subsidiary, Viva China Development Limited, purchased an additional 19.231 million shares of Li Ning Company Ltd on the open market through the Stock Exchange on September 7, 2026. Following this acquisition, the purchaser holds 492 million shares of Li Ning, representing approximately 19.04% of the company's total issued shares. Li Ning continues to be accounted for as an associate of the group, and the group will continue to share in Li Ning's profits less losses.
CSPC Pharmaceutical Group (01093) has initiated its Phase II clinical trial in China for SYH2085 tablets, a small molecule inhibitor targeting the PA subunit of influenza virus RNA polymerase, classified as a Class 1 chemical drug. The product converts in vivo to its main active metabolite SYH2085A-01207, which selectively inhibits the endonuclease activity of the viral polymerase PA subunit, thereby suppressing influenza virus replication. The group previously received the Drug Clinical Trial Approval Notice from the National Medical Products Administration in December 2025.
In dark pool trading ahead of its Hong Kong listing on Tuesday, September 8, Longsys Electronics (09976) closed at HK$234 per share, representing a 0.85% discount from its offer price of HK$236. With a board lot of 50 shares, each lot incurred a paper loss of HK$100 before fees.
Unisound AI Technology (09678) has announced consecutive wins in multiple benchmark smart healthcare projects with a combined value approaching 100 million yuan. The projects span smart medical systems for leading tier-three hospitals, intelligent fund supervision platforms for major insurance institutions, and regional medical intelligence construction initiatives, signaling that the company's proprietary "U2-Med" medical model is rapidly transitioning from technical advantages to scalable commercial outcomes.
Comments